Bhayana Sagar, Song Feifei, Jacob Jidhin, Fadda Paolo, Denko Nicholas C, Xu-Welliver Meng, Chakravarti Arnab, Jacob Naduparambil K
Department of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210.
Radiat Res. 2017 Dec;188(6):626-635. doi: 10.1667/RR14828.1. Epub 2017 Oct 4.
Radiation nephropathy is one of the common late effects in cancer survivors who received radiotherapy as well as in victims of radiation accidents. The clinical manifestations of radiation nephropathy occur months after exposure. To date, there are no known early biomarkers to predict the future development of radiation nephropathy. This study focuses on the development of urinary biomarkers providing readout of acute responses in renal tubular epithelial cells. An amplification-free hybridization-based nCounter assay was used to detect changes in mouse urinary miRNAs after irradiation. After a single LD of total-body irradiation (TBI) or clinically relevant fractionated doses (2 Gy twice daily for 3 days), changes in urinary levels of microRNAs followed either an early pattern, peaking at 6-8 h postirradiation and gradually declining, or later pattern, peaking from 24 h to 7 days. Of 600 miRNAs compared, 12 urinary miRNAs showed the acute response and seven showed the late response, common to both irradiation protocols. miR-1224 and miR-21 were of particular interest, since they were the most robust acute and late responders, respectively. The early responding miR-1224 also exhibited good dose response after 2, 4, 6 and 8 Gy TBI, indicating its potential use as a biomarker for radiation exposure. In situ hybridization of irradiated mouse kidney sections and cultured mouse primary renal tubular cells confirmed the tubular origin of miR-1224. A significant upregulation in hsa-miR-1224-3p expression was also observed in human proximal renal tubular cells after irradiation. Consistent with mouse urine data, a similar expression pattern of hsa-miR-1224-3p and hsa-miR-21 were observed in urine samples collected from human leukemia patients preconditioned with TBI. This proof-of-concept study shows the potential translational utility of urinary miRNA biomarkers for radiation damage in renal tubules with possible prediction of late effects.
放射性肾病是接受放射治疗的癌症幸存者以及辐射事故受害者常见的晚期效应之一。放射性肾病的临床表现发生在暴露数月后。迄今为止,尚无已知的早期生物标志物可预测放射性肾病的未来发展。本研究聚焦于开发可提供肾小管上皮细胞急性反应读数的尿液生物标志物。基于无扩增杂交的nCounter分析用于检测照射后小鼠尿液中微小RNA(miRNA)的变化。在单次全身照射(TBI)的致死剂量或临床相关的分次剂量(每天两次,每次2 Gy,共3天)后,尿液中miRNA水平的变化呈现早期模式,在照射后6 - 8小时达到峰值并逐渐下降,或呈现晚期模式,在24小时至7天达到峰值。在比较的600种miRNA中,12种尿液miRNA显示出急性反应,7种显示出晚期反应,这两种照射方案都有。miR - 1224和miR - 21特别受关注,因为它们分别是最强的急性和晚期反应者。早期反应的miR - 1224在2、4、6和8 Gy TBI后也表现出良好的剂量反应,表明其作为辐射暴露生物标志物的潜在用途。照射后小鼠肾脏切片和培养的小鼠原代肾小管细胞的原位杂交证实了miR - 1224的肾小管来源。在人近端肾小管细胞照射后也观察到hsa - miR - 1224 - 3p表达显著上调。与小鼠尿液数据一致,在接受TBI预处理的人类白血病患者收集的尿液样本中观察到hsa - miR - 1224 - 3p和hsa - miR - 21有类似的表达模式。这项概念验证研究表明,尿液miRNA生物标志物在预测肾小管辐射损伤及可能的晚期效应方面具有潜在的转化应用价值。